particularly where the underlying allergen is unable to be removed. This is of relevance for patients with concurrent AD as they are more likely to respond to dupilumab due to the synergistic effect of improving underlying barrier function, making the skin less susceptible to allergens. IBOA is a frequently implicated culprit allergen that found in glucose monitoring devices and insulin pumps. Thus, with greater uptake of these devices, clinicians should be aware of the potential for contact allergy. Our case is the first to demonstrate that dupilumab is a well-tolerated and efficacious therapeutic option for patients with treatment resistant ACD to IBOA, without disrupting or interfering with their diabetic management.

Alexis Arasu1 | Gayle Ross2
1Alfred Health, Melbourne, Victoria and 2Department of Dermatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

REFERENCES
1. Nath N, Reeder M, Atwater AR. Isobornyl acrylate and diabetic devices steal the Show for the 2020 American Contact Dermatitis Society Allergen of the Year. Cutis 2020; 105: 283–5.
2. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011; 345: d3805.
3. Machler BC, Sung CT, Darwin E et al. Dupilumab use in allergic contact dermatitis. J. Am. Acad. Dermatol. 2019; 80: 280–281.e1.
4. Rowe A, Bunker CB. Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. Contact Dermatitis 1998; 38: 56–9.
5. Desrosiers A, Huynh T, Helms S et al. The role of dupilumab in managing allergic contact dermatitis. SKIN J. Cutan. Med. 2019; 5: 254–8.
6. Chipalkatti N, Lee N, Zancanaro P et al. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis. J. Am. Acad. Dermatol. 2019; 80: 1166–7.

doi: 10.1111/ajd.13742

Case Letter

Dear Editor,

A case of toxic epidermal necrolysis after ChAdOx1 nCoV-19 (AZD1222) vaccination

A healthy 48-year-old woman presented to hospital with a worsening erythematous eruption, with onset 14 days after receiving her first dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine. Aside from minor discomfort at the

Figure 1  (a) & (b) show clinical images taken on day 4 of admission, showing denuded skin on the anterior trunk (a) with flaccid bullae measuring up to 40mm in diameter and with a total BSA of epidermally detached skin to 15%. Also present were erosions of the hard palate (b) and labia majora (not shown); there was no involvement of the vaginal mucosa or conjunctiva. (c) & (d) show clinical images taken on day 6 of admission, demonstrating progression of exfoliation on the trunk.

The authors do not declare any conflicts of interest, disclosures or funding sources.

Patient consent was obtained for this manuscript as per Australasian Journal of Dermatology author guidelines and was prepared in accordance with the CARE guidelines.

No ethics approval was required for this manuscript.

© 2021 The Australasian College of Dermatologists
injection site that spontaneously resolved, she denied any other post-vaccination symptoms. A pruritic eruption initially appeared on her chest, extending rapidly to the trunk, limbs and orogenital mucosa, with florid exfoliation. There were associated fevers, nausea and skin tenderness. Past medical history was unremarkable, with no other medications preceding the eruption. She was prescribed betamethasone valerate 0.02% cream with twice daily topical application, as well as fexofenadine 180 mg once daily per orally by her GP for her pruritic eruption with no relief. Paracetamol 1 g four times daily and ibuprofen 500 mg three times daily per orally were taken for her fever with no improvement. The patient had taken paracetamol, ibuprofen and fexofenadine previously with no issues.

Examination showed a confluent erythematous maculopapular eruption with a positive Nikolsky sign and orogenital mucosal involvement (Fig. 1). Skin biopsies demonstrated full-thickness epidermal necrosis, pauci-inflammatory dermis, and negative direct immunofluorescence (Fig. 2). Serology did not reveal any active infections with *mycoplasma pneumoniae*, herpes simplex virus or adenovirus. Screening tests were performed for HIV, hepatitis B, hepatitis C, tuberculosis and Strongyloides infection, which all returned negative results. Aside from mildly increased liver transaminases, blood differential and chemistry were within normal limits.

She was admitted to a burns unit for management of Toxic Epidermal Necrolysis (TEN) due to ChAdOx1 nCoV-19 vaccine. Her SCORTEN at time of admission was 2, scoring for age (>40 years) and more than 10% body surface area (BSA) of epidermal detachment. Treatment with adalimumab, a human IgG1 monoclonal antibody to Tumour Necrosis Factor-alpha (TNF-α), was given as an 80mg stat dose via subcutaneous injection. Two further doses were administered on days 3 and 5 after which progression of the eruption ceased. Detachment of involved skin continued up to 28 days of admission, with 90% of BSA involved. She made a full recovery and was discharged home after 35 days.

TEN is a severe cutaneous adverse reaction and a medical emergency, with a mortality rate of up to 50%. SJS/TEN have a combined incidence between 2-7 cases per million annually, whilst vaccine-induced SJS/TEN is even rarer with less than 0.1 cases of SJS/TEN per million doses of influenza vaccine administered between 2010 to 2017.2,5

TEN following ChAdOx1 nCoV-19 vaccination may relate to its immunogenicity to stimulate a robust CD8+ CTL response, which peaks between 7 and 28 days after vaccination, consistent with our patients’ onset of exfoliative bullous eruptions 14 days after first exposure.4

Figure 2 Shows histopathology of skin biopsy demonstrating partial- to full-thickness epidermal necrosis, subepidermal split, basal vacuolation and scattered superficial dermal perivascular lymphocytes (x40, x200 & x100, H&E). Direct immunofluorescence was negative for fibrinogen, C5, IgA, IgG or IgM deposition.

TNF-2 is elevated in serum and skin samples of TEN patients, although the extent TNF-2 induces keratinocyte apoptosis in TEN is unknown.2 The efficacy of TNF-2 inhibitors to abrogate TEN has been demonstrated previously with Etanercept.5 Adalimumab may prove to be a highly
effective treatment for TEN, although larger randomised
control studies are required to validate this.

We raise awareness of the possibility of TEN following
ChAdOx1 nCoV-19 vaccination and encourage clinicians to
have a high index of suspicion for individuals with a
rapidly progressive cutaneous eruption following ChAdOx1
nCoV-19 vaccination to minimise delay in diagnosis and
referral to a burns unit. However, we caution that this is a
very rare event, the risk of which is minimal compared to
the morbidity and mortality of SARS-CoV-2. It should not
deter the wider community from receiving this or any other
vaccine.

Ashod Kherlopian MChD, BSc (Hons1)1  Cathy
Zhao MBBS, MMed, MSc, DCH1  Ludi Ge MBBS
(Hons), MPH1  Emily Forward MBBS, MBA1  Gayle Fischer MBBS, MD, OAM, FACD2

1Department of Dermatology and 2Royal North Shore
Hospital, St Leonards, New South Wales Australia

REFERENCES
1. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrol-
ysis: Part II. Prognosis, sequelae, diagnosis, differential diagno-
sis, prevention, and treatment. J. Am. Acad. Dermatol. 2013; 69:
187.e1–187.e16: quiz 203–4.
2. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrol-
ysis: Part I. Introduction, history, classification, clinical features,
systemic manifestations, etiology, and immunopathogenesis.
J. Am. Acad. Dermatol. 2013; 69: 173.e1–173.e13; quiz 85-6.
3. Su JR, Haber P, Ng CS et al. Erythema multiforme, Stevens
Johnson syndrome, and toxic epidermal necrolysis reported
after vaccination, 1999–2017. Vaccine 2020; 38: 1746–52.
4. Ewer KJ, Barrett JR, Belij-Rammerstorfer S et al. T cell and
antibody responses induced by a single dose of ChAdOx1 nCoV-
19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat. Med.
2021; 27: 270–8.
5. Paradisi A, Abeni D, Bergamo F et al. Etanercept therapy for toxic
epidermal necrolysis. J. Am. Acad. Dermatol. 2014; 71: 278–85.
doi: 10.1111/ajd.13679

Case Letter

Dear Editors,

Amelanotic melanoma of the nail apparatus complicated
with digital mucous cyst

Amelanotic melanoma of the nail apparatus (AMNA) is a
rare melanoma subtype which is easily overlooked or
diagnosed late because of the lack of pigmentation and
various mimicking benign lesions such as pyogenic granu-
loma.1,2 Although digital mucous cysts are known as one of
the misdiagnoses of acral melanoma,3 herein we pre-
sent an instructive case of AMNA hidden by the existence
of digital mucous cyst on the same finger concurrently.

A 75-year-old Japanese woman visited our hospital with a
2-year history of a nail deformity on the left middle finger
(Fig. 1A). Additionally the patient harboured a painless
round subcutaneous nodule on the dorsal side of the same
finger between the distal interphalangeal (DIP) joint and
proximal nail fold (Fig. 1A). Clear mucus discharge was
observed on diagnostic puncture; therefore she was diag-
nosed with a nail deformity secondary to a digital mucous
cyst and treated with several drainages of the cyst’s mucu-

© 2021 The Australasian College of Dermatologists